Latest News on TEM

Financial News Based On Company


Advertisement
Advertisement

Tempus AI evp sells $422,460 in shares for tax obligations By Investing.com

https://uk.investing.com/news/stock-market-news/tempus-ai-evp-sells-422460-in-shares-for-tax-obligations-93CH-4994758
Andrew Polovin, EVP and Chief Legal Officer at Tempus AI (NASDAQ:TEM), sold 6,704 shares of Class A Common Stock worth $422,460 on November 17, 2026. These "sell to cover" transactions were made to fulfill tax obligations related to restricted stock unit vesting, not discretionary sales. The stock has seen a 16.75% decline over the past week but is up almost 30% over six months, with InvestingPro analysis suggesting it is currently overvalued.

Stock awards vested, and the legal chief of Tempus AI (TEM) sold 6,704 shares to cover taxes.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-219f7b70d1f7.html
Andrew Polovin, EVP and Chief Legal Officer of Tempus AI (TEM), sold 6,704 Class A shares on November 17, 2026, to cover statutory tax withholding obligations related to restricted stock unit vesting. The sales, totaling approximately $422,000 across three transactions at weighted-average prices between $62.33 and $64.02 per share, were non-discretionary and mandated by the company's equity incentive plans. Following these transactions, Polovin directly holds 128,485 Class A common shares.

Ryan Fukushima sold 10,247 Tempus AI (TEM) shares in three required trades tied to vested stock awards.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-f62c7eab3aa4.html
Ryan Fukushima, CEO of Tempus AI (TEM), reported three non-discretionary sales of a total of 10,247 Class A shares on November 17, 2026. These "sell-to-cover" transactions were mandated by the company's equity plan to satisfy statutory tax withholding obligations related to vested restricted stock units. The shares were sold at weighted-average prices ranging from $62.33 to $64.02, and Fukushima's spouse indirectly holds an additional 15,794 Class A shares.

To cover required tax withholding, the Tempus AI (TEM) CEO sold 5,367, 10,225 and 1,482 shares.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-496fd70af0f8.html
Tempus AI (TEM) CEO and Chairman Eric P. Lefkofsky reported three non-discretionary sales of Class A common stock on November 17, 2026. These sales, totaling 17,074 shares, were executed to cover statutory tax withholding obligations related to restricted stock unit vesting. The transactions involved shares sold at weighted-average prices of $62.33, $63.23, and $64.02 per share, respectively, and were mandated by the issuer's equity plan.

Form 8K Tempus AI Inc For: 18 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-tempus-ai-inc-for-18-november-93CH-4967061
The article announces that Tempus AI Inc. filed a Form 8K on November 18, 2026. The filing is a standard regulatory document often used to report significant events that shareholders should know about. The article provides minimal detail beyond the filing's existence and date.
Advertisement

Form 8K Tempus AI Inc For: 18 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-tempus-ai-inc-for-18-november-93CH-4990805
This article reports that Tempus AI Inc. filed a Form 8K on November 18, 2026. A Form 8K is a crucial SEC filing that companies use to announce unscheduled material events or corporate changes that shareholders should know about. The article includes the stock symbol TEM and a slight positive change for the day.

PSNL Merger Investigation: Personalis Investigated Over $16.25 per Share Take-Private Merger – Contact BFA Law if You Hold Shares

https://www.globenewswire.com/news-release/2026/11/18/3405495/0/en/psnl-merger-investigation-personalis-investigated-over-16-25-per-share-take-private-merger-contact-bfa-law-if-you-hold-shares.html
Bleichmar Fonti & Auld LLP is investigating the proposed take-private merger of Personalis, Inc. (NASDAQ: PSNL) by Tempus AI, Inc. for $16.25 per share. The investigation focuses on potential breaches of fiduciary duty by Tempus AI, which already held a significant stake in Personalis and had an existing commercial relationship. Shareholders are encouraged to contact BFA Law to discuss their rights regarding the fairness of the merger price and compliance with Delaware law.

NN, Fluence Energy, GRAIL, Tempus AI, and CSW shares are falling, what you need to know

https://stockstory.org/us/stocks/nasdaq/nnbr/news/why-up-down/nn-fluence-energy-grail-tempus-ai-and-csw-shares-are-falling-what-you-need-to-know
Shares of NN, Fluence Energy, GRAIL, Tempus AI, and CSW fell significantly in the afternoon session due to leadership uncertainty at Nvidia, including the resignation of CEO Jensen Huang. This shakeup at a pivotal AI chipmaker triggered broad declines across the artificial intelligence sector and wider technology markets, as investors reassessed growth trajectories and supply chain stability. While the market often overreacts, such drops can present opportunities for high-quality stocks.

Form 144 Tempus AI For: 11 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-tempus-ai-for-11-november-93CH-4975780
This article reports on a Form 144 filing for Tempus AI, dated November 11. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider trading activity. The brief article, published by Investing.com, also notes a slight dip in Tempus AI's stock (TEM) by 1.38%.

Pictet Asset Management Holding SA Buys 486,493 Shares of Tempus AI, Inc. $TEM

https://www.marketbeat.com/instant-alerts/filing-pictet-asset-management-holding-sa-buys-486493-shares-of-tempus-ai-inc-tem-2026-11-11/
Pictet Asset Management Holding SA significantly increased its stake in Tempus AI, Inc. by purchasing 486,493 shares in the third quarter, bringing its total to 502,897 shares valued at $41.2 million. This comes as Tempus AI reported strong quarterly earnings of $0.07 per share, surpassing analyst estimates, with a 23.1% year-over-year revenue increase to $411.5 million. Despite substantial insider selling, analysts maintain a "Hold" consensus rating with an average price target of $79.37 for the stock.
Advertisement

Weekly Recap: Oncology and Alzheimer’s deals and analyst target hikes

https://www.tradingview.com/news/tradingview:59e496a10ebca:0-weekly-recap-oncology-and-alzheimer-s-deals-and-analyst-target-hikes/
Tempus AI (NASDAQ: TEM) recently reported a 33% increase in third-quarter Data and Applications revenue and secured significant five-year deals with Bristol Myers Squibb and Pathos, potentially generating up to $192.5 million. The company also entered a multi-year agreement with Moderna and Merck to support the commercialization of intismeran autogene. Additionally, Tempus AI received FDA clearances for its ECG-PH and ECG-MR products and saw multiple firms raise their price targets for its stock.

Tempus AI, Inc. (NASDAQ:TEM) Stock Has Average Target Price of $79.37

https://www.marketbeat.com/instant-alerts/consensus-tempus-ai-inc-nasdaq-tem-stock-has-average-target-price-of-7937-2026-11-06/
Tempus AI (NASDAQ:TEM) has received a consensus "Hold" rating from 22 brokerages, with an average 12-month price target of $79.37. This follows the company's strong quarterly earnings report, where it surpassed revenue and EPS expectations. Several firms adjusted their price targets upward, reflecting positive sentiment despite some insider selling.

Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up

https://seekingalpha.com/article/4964797-tempus-ai-stock-q3-strengthens-platform-thesis-cash-returns-need-to-catch-up
Tempus AI is rated 'hold' due to its current valuation already reflecting significant future success. The platform's strength lies in connecting diagnostic data with clinical outcomes, driving research value and recurring revenue potential. While Q3 2026 showed strong revenue growth and improving adjusted EBITDA, GAAP losses persist, and sustained free cash flow and operating leverage are yet to be proven.

Tempus AI, Inc. (NASDAQ:TEM) Just Reported And Analysts Have Been Lifting Their Price Targets

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-inc-nasdaqtem-just-reported-and-analysts-have-been
Tempus AI, Inc. (NASDAQ:TEM) recently released its third-quarter results, showing revenues in line with expectations at US$412m, but with statutory losses much smaller than anticipated at US$0.08 per share. Despite an initial negative market response, analysts have largely reconfirmed their loss per share estimates for next year and expect the company to continue growing faster than the wider industry. While the average price target fell, there was a nice increase, indicating analysts see improving intrinsic value.

Tempus AI Director David R. Epstein Executes Sale of 370 Shares at $74.29 Under Rule 10b5-1 Plan

https://kalkinemedia.com/us/news/announcements/tempus-ai-director-david-r-epstein-executes-sale-of-370-shares-at-7429-under-rule-10b5-1-plan
Tempus AI Director David R. Epstein sold 370 shares of Class A Common Stock at $74.29 per share on November 2, 2026. This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on August 27, 2024. Following the sale, Epstein retains a direct holding of 30,474 shares of Tempus AI.
Advertisement

A 100,000-share grant at Tempus AI (TEM) vests in eight quarters starting January 15, 2027.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-a9b08ea4052c.html
Tempus AI officer Ryan Fukushima received a grant of 100,000 restricted stock units (RSUs) on November 2, 2026, which will vest in eight equal quarterly installments beginning January 15, 2027. His spouse simultaneously sold 80 shares at $74.29 each under a pre-arranged trading plan. Following these transactions, Fukushima directly holds 662,463 shares, and his spouse indirectly holds 15,794 shares.

Selling at $74.29 a share, Tempus AI (TEM) director Epstein retains 30,474 shares.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-0ed17b9df0ab.html
Tempus AI, Inc. director David R. Epstein sold 370 shares of Class A Common Stock on November 2, 2026, at a price of $74.29 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in August 2024. Following the sale, Mr. Epstein directly retains 30,474 shares of the company.

Tempus AI (NASDAQ:TEM) Posts First Adjusted Profit as Oncology and Data Demand Accelerate

https://kalkinemedia.com/us/stocks/artificial-intelligence/tempus-ai-nasdaqtem-posts-first-adjusted-profit-as-oncology-and-data-demand-accelerate
Tempus AI (NASDAQ:TEM) reported its first adjusted profit and record third-quarter revenue, driven by accelerated oncology testing growth and strong demand for its data and applications segment. The company also raised its full-year revenue outlook, signaling a positive turn for the AI-driven healthcare platform. These results demonstrate Tempus AI's ability to translate its extensive data scale into significant financial gains, despite a challenging broader technology market.

Tempus AI Q3 revenue rises 23% to $411.5m

https://grafa.com/en/news/united-states/tempus-ai-q3-2026-revenue-rises-23-percent-raises-guidance
Tempus AI reported a 23% year-over-year increase in Q3 2026 revenue, reaching $411.5 million and surpassing analyst expectations. The company also reported adjusted EPS of $0.07 against an expected loss and raised its full-year 2026 revenue guidance to $1.60 billion–$1.605 billion. This strong performance, driven by growth in diagnostics and data/applications, led to a roughly 4% rise in Tempus shares.

Planned sales of 250,000 Tempus AI (TEM) shares executed at $66.69 to $72.84.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-eb47b21e50b4.html
Tempus AI's CEO and Chairman, Eric P. Lefkofsky, reported the sale of 250,000 Class A common shares by various entities on October 27, 2026. The sales were made under a Rule 10b5-1 trading plan adopted in March 2026, with weighted-average prices ranging from $67.36 to $72.31 per share, and execution prices from $66.69 to $72.84. This transaction significantly impacts the reported indirect and direct holdings of Class A Common Stock.
Advertisement

Form 144 Tempus AI For: 27 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-tempus-ai-for-27-october-93CH-4907608
The article "Form 144 Tempus AI For: 27 October" from Investing.com is a brief report indicating a Form 144 filing for Tempus AI (TEM) on October 27, 2026. This type of filing typically relates to the intent to sell restricted or control securities. The article includes the stock symbol TEM and its performance, showing a 6.18% increase.

Weekly Recap: Bristol Myers Squibb data deal and AI H&E >80%

https://www.tradingview.com/news/tradingview:397f6d98740db:0-weekly-recap-bristol-myers-squibb-data-deal-and-ai-h-e-80/
Tempus AI, Inc. (NASDAQ: TEM) secured a multi-year agreement with Bristol Myers Squibb to provide de-identified multimodal oncology data and access to its Lens AI platform through 2031. Additionally, Tempus AI's AI H&E pre-screen for advanced non-small cell lung cancer demonstrated over 80% sensitivity across 12 biomarkers in a large-scale analysis of 60,459 cases, with several biomarkers exceeding 90% sensitivity.

Tempus AI receives European IVDR certification for xR cancer profiling

https://mugglehead.com/tempus-ai-xr-rna-cancer-profiling-europe-ivdr-certification/
Tempus AI announced it has received Class C certification under the European Union's In Vitro Diagnostic Regulation (IVDR) for its xR solid-tumour RNA profiling assay. This certification supports continued EU access for the assay beyond the 2028 transition deadline and covers the company's quality management system for next-generation sequencing devices used in cancer genomic profiling. The xR assay detects gene rearrangements and splice variants, with RNA analysis capable of identifying actionable gene fusions missed by DNA testing alone.

Tempus AI stock may move 8.7% on Nov. 2 earnings report

https://www.investing.com/news/stock-market-news/tempus-ai-stock-may-move-87-on-nov-2-earnings-report-93CH-4973105
Tempus AI Inc. Class A shares are projected to move 8.7% when the company releases its earnings report on November 2nd, according to options data. Historically, the stock's actual movement has often differed from the options-implied amount following previous earnings announcements. For instance, on July 30, the stock declined 6.6% against a 6.5% implied move, and on February 24, 2025, it dropped 33.9% against a 12.0% implied move.

Tempus AI, Inc. Class A Estimates – HAN:F3M

https://www.tradingview.com/symbols/HAN-F3M/financials-estimates/
The article provides a financial overview of Tempus AI, Inc. Class A (HAN:F3M) on the Hannover Stock Exchange, emphasizing its financial actuals and estimates. It allows users to explore reported financial data and analyst estimates across various financial statements, compare actual results with estimates, and visualize trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.
Advertisement

Tempus AI, Inc. (TEM) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/TEM/
This article provides an overview of Tempus AI, Inc. (TEM) stock, including its current price, market data, and company profile. Tempus AI operates as a healthcare technology company offering a platform for diagnostic capabilities, analytics, and data repository, along with various diagnostic services and AI-powered applications. The report also details recent performance, earnings trends, and analyst ratings for the company.

Current ratio of Tempus AI, Inc. Class A – HAN:F3M

https://www.tradingview.com/symbols/HAN-F3M/financials-statistics-and-ratios/current-ratio/
The article focuses on the current ratio of Tempus AI, Inc. Class A (HAN:F3M) on the Hannover Stock Exchange. It provides a financial snapshot for the company, accessible through TradingView's platform, indicating that market data is provided by ICE Data Services and FactSet. The content is primarily a navigation and footer heavy page from TradingView, with little substantive article text.

A trading plan governed the sale of 10,281 Tempus AI (TEM) shares by its diagnostics CEO at $85 each.

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-8fad9034c8c3.html
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), sold 10,281 shares of Class A Common Stock at $85 per share on September 25, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026. Following the sale, Schoenherr directly holds 76,740 shares.

Tempus AI, Inc. Class A Bonds — Corporate Bond Rates

https://www.tradingview.com/symbols/HAN-F3M/bonds/
This article lists corporate bond rates for Tempus AI, Inc. Class A, providing details on yield to worst, price, coupon, maturity date, outstanding amount, and face value for two different bonds. It serves as a resource for investors seeking stable investment options during market volatility.

Tempus AI receives FDA clearance for heart valve AI tool

https://www.investing.com/news/company-news/tempus-ai-receives-fda-clearance-for-heart-valve-ai-tool-93CH-4920150
Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECG-MR product. This AI tool analyzes standard 12-lead resting electrocardiograms to detect signs associated with undiagnosed moderate or severe mitral regurgitation. The company's portfolio now includes four FDA-cleared ECG-AI products, aiming to help identify high-risk patients for further evaluation.
Advertisement

Tempus AI CAO Ryan Bartolucci sells $529,650 in stock By Investing.com

https://in.investing.com/news/stock-market-news/tempus-ai-cao-ryan-bartolucci-sells-529650-in-stock-93CH-5608039
Ryan Bartolucci, Chief Accounting Officer at Tempus AI, Inc., recently sold 7,062 shares of Class A Common Stock for $529,650, at a price of $75.00 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in June 2026, and after the transaction, Mr. Bartolucci directly holds 60,804 shares. The stock has since increased to $85.01, representing a 99% surge over the last six months, though InvestingPro analysis suggests the company may be overvalued.

Tempus AI EVP Andrew Polovin sells 2,951 shares for $221,325

https://www.investing.com/news/insider-trading-news/tempus-ai-evp-andrew-polovin-sells-2951-shares-for-221325-93CH-4919256
Tempus AI EVP Andrew Polovin sold 2,951 shares of the company's Class A Common Stock for $221,325 on September 17, 2026, pursuant to a pre-arranged trading plan. Following the sale, Tempus AI's stock price increased, with InvestingPro suggesting it is overvalued. The company has recently received varied analyst ratings, including upgrades to Overweight from Piper Sandler and Cantor Fitzgerald, and a Neutral rating from Goldman Sachs and Rothschild Redburn.

Tempus AI CAO Ryan Bartolucci sells $529,650 in stock

https://www.investing.com/news/insider-trading-news/tempus-ai-cao-ryan-bartolucci-sells-529650-in-stock-93CH-4919284
Tempus AI's Chief Accounting Officer, Ryan Bartolucci, sold 7,062 shares of Class A Common Stock for $529,650 on September 17, 2026, through a pre-planned trading arrangement. Following this transaction, Bartolucci still holds over 60,000 shares. The sale occurred while the stock had surged 99% in six months, though InvestingPro analysis suggests the company is currently overvalued.

Form 144 Tempus AI For: 27 September By Investing.com

https://in.investing.com/news/stock-market-news/form-144-tempus-ai-for-27-september-93CH-5607774
This article announces the filing of Form 144 for Tempus AI on September 27. It provides financial data for various global markets, including indices, commodities, and currencies, and features trending stocks and popular articles from Investing.com. The content focuses on market performance and news updates relevant to investors.

Tempus AI CEO-linked entities sell 250,000 shares

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-ef0d16ce4e0e.html
Entities linked to Tempus AI (TEM) CEO and Chairman Eric P. Lefkofsky sold a total of 250,000 Class A common shares on September 22, 2026. These indirect sales were conducted by Gray Media, LLC, Blue Media, LLC, Lefkofsky Family Foundation, and Vas.org Foundation, under a Rule 10b5-1 trading plan. The shares were sold at weighted-average prices ranging from $76.57 to $78.86 per share.
Advertisement

Tempus AI Chief Accounting Officer Sells $529,650 of Stock

https://finance.yahoo.com/markets/stocks/articles/tempus-ai-chief-accounting-officer-130001110.html
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 7,062 shares of Class A Common Stock worth $529,650 on September 17, 2026, under a pre-arranged Rule 10b5-1 trading plan. Despite this sale, which represented a small percentage of his total holdings, he still retains 60,804 shares. The article notes that this transaction should not alarm investors, as the company has seen significant revenue growth, though it remains unprofitable.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Avantor (AVTR)

https://www.theglobeandmail.com/investing/markets/stocks/TEM/pressreleases/4749554/analysts-have-conflicting-sentiments-on-these-healthcare-companies-tempus-ai-inc-class-a-tem-and-avantor-avtr/
Goldman Sachs initiated coverage on Tempus AI, Inc. Class A (TEM) with a Hold rating and a $75.00 price target. Meanwhile, Wells Fargo maintained a Buy rating on Avantor (AVTR) with a price target of $16.00. Overall, analysts show mixed sentiments for both healthcare companies, with Tempus AI having a "Moderate Buy" consensus and Avantor a "Hold" consensus.

Tempus AI chief accounting officer sells $529,650 in stock

https://www.investing.com/news/insider-trading-news/tempus-ai-chief-accounting-officer-sells-529650-in-stock-93CH-4908030
Ryan M. Bartolucci, Tempus AI's Chief Accounting Officer, sold 7,062 shares of Class A common stock for $529,650 on September 17, 2026. This sale, executed via a Rule 10b5-1 trading plan, followed a significant 32% surge in the company's stock price over the past week. Despite the sale, Bartolucci still directly owns 60,804 shares, and the company has recently received positive analyst attention and price target increases due to its pending acquisition of Personalis.

Tempus AI (TEM) CAO sells stock in preset 10b5-1 trade

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-776c10620481.html
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 7,062 shares of Class A Common Stock at $75.00 per share on September 17, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted on June 5, 2026. Following the transaction, Bartolucci directly holds 60,804 shares.

EVP at Tempus AI (TEM) sells shares in preset plan trade

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-170687d183f0.html
Tempus AI's EVP and Chief Legal Officer, Andrew Polovin, sold 2,951 shares of Class A Common Stock at $75.00 per share on September 17, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Polovin directly holds 135,189 shares of TEM.
Advertisement

Tempus AI (TEM) data chief’s spouse sells 700 shares under plan

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-b52b8b439eb4.html
Ryan Fukushima, Tempus AI's CEO of Data, had his spouse sell 700 shares of Class A Common Stock at $70.00 per share on September 16, 2026. This transaction was executed under a Rule 10b5-1 trading plan established on March 12, 2026. Following the sale, Fukushima's indirect holdings through his spouse are 15,874 shares, while his direct holdings are 562,463 shares.

Tempus AI’s EVP, chief legal officer, sells $221,325 in stock By Investing.com

https://ca.investing.com/news/stock-market-news/tempus-ais-evp-chief-legal-officer-sells-221325-in-stock-93CH-4845553
Tempus AI's Executive Vice President and Chief Legal Officer, Andrew Polovin, sold 2,951 shares of the company's Class A Common Stock for $221,325 on September 17, 2026, at a price of $75.0 per share. This sale was conducted under a Rule 10b5-1 trading plan. The stock has since increased by 32% to $77.84, with InvestingPro noting it as overvalued and highly volatile, while analysts have issued varied ratings and price targets following recent strategic developments, including the acquisition of Personalis.

Tempus AI’s EVP, chief legal officer, sells $221,325 in stock By Investing.com

https://za.investing.com/news/stock-market-news/tempus-ais-evp-chief-legal-officer-sells-221325-in-stock-93CH-4470557
Andrew Polovin, EVP and Chief Legal Officer at Tempus AI (TEM), sold 2,951 shares of Class A Common Stock for $221,325 on September 17, 2026. The sale was made through a Rule 10b5-1 trading plan adopted in August 2025. This transaction comes amidst recent analyst coverage and strategic developments for Tempus AI, including its acquisition of Personalis, which has led to varied price target adjustments and ratings from firms like H.C. Wainwright, Piper Sandler, and Cantor Fitzgerald.

Tempus AI CEO, data Ryan Fukushima sells $49,000 in stock By Investing.com

https://in.investing.com/news/stock-market-news/tempus-ai-ceo-data-ryan-fukushima-sells-49000-in-stock-93CH-5598853
Tempus AI's CEO and Data, Ryan Fukushima, sold 700 shares of the company's Class A Common Stock for $49,000 on September 16, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, the stock saw a 31.9% gain in the past week, though InvestingPro deems it overvalued. The company has also received several positive analyst ratings and price target increases recently due to strategic acquisitions and advancements in genomic testing.

Tempus AI (TEM) director’s stock sale follows preset plan

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-4b7c9a34cddd.html
A director at Tempus AI (TEM), David R. Epstein, sold 250 Class A shares at $65.55 per share on September 1, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2024. Following the sale, Epstein directly holds 30,844 shares of Tempus AI Class A Common Stock.
Advertisement

Tempus AI (TEM) CEO’s 200,000-share sale was preplanned

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-5f46a353f3fb.html
Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky sold 200,000 shares of Class A common stock on September 17, 2026, through affiliated entities. The sale, valued at approximately $16.11 million, was executed at weighted average prices between $80.00-$80.92 and $81.00-$81.26 per share. This transaction was preplanned under a Rule 10b5-1 trading plan adopted on March 8, 2026.

Could Tempus AI (NASDAQ:TEM) Change the NASDAQ AI Stocks Narrative?

https://kalkinemedia.com/us/stocks/artificial-intelligence/could-tempus-ai-nasdaqtem-change-the-nasdaq-ai-stocks-narrative
Tempus AI (NASDAQ:TEM) is in focus after launching an initiative to build a large disease-specific whole-genome and clinical-outcomes dataset for AI-driven healthcare research. This development places commercial adoption of AI back in the spotlight, with market participants scrutinizing its impact on computing capacity, customer use, and deployment economics. The article emphasizes that consistent operational execution and clear disclosures will be crucial in demonstrating durable progress for Tempus AI amidst broader market concerns about inflation and interest rates.

Tempus AI (TEM) CEO sells 11.8K shares at $70 on August 25, 2026

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-36e05abc816c.html
Eric P. Lefkofsky, CEO and Chairman of Tempus AI (TEM), indirectly sold 11,848 shares of Class A Common Stock on August 25, 2026, through Vas.org Foundation. The shares were sold at weighted average prices of $69.83 and $70.58, as part of a pre-established Rule 10b5-1 trading plan. Post-transaction, Lefkofsky retains significant direct and indirect holdings in the company.

Tempus AI (TEM) CEO's spouse sells 30,846 shares under trading plan

https://www.stocktitan.net/sec-filings/TEM/form-4-tempus-ai-inc-insider-trading-activity-5500bd5516ea.html
Tempus AI's CEO, Data Fukushima Ryan, reported an indirect sale of 30,846 Class A Common Stock shares through his spouse's account on September 1, 2026. These open-market transactions were executed under a pre-planned Rule 10b5-1 trading plan adopted on March 12, 2026. Following these sales, Fukushima Ryan directly holds 562,463 shares of Class A Common Stock.

Tempus AI Director Nadja West Sells 3,000 Shares for $207,000

https://www.fool.com/coverage/filings/2026/09/02/tempus-ai-director-nadja-west-sells-3000-shares-for-207000/
Tempus AI Director Nadja West sold 3,000 shares of Class A Common Stock for $207,000 on August 28, 2026, according to an SEC filing. This transaction was part of a pre-established Rule 10b5-1 trading plan and represents 9% of her direct equity stake, leaving her with 31,981 shares. The company, a healthcare technology firm, is still in an investment phase, experiencing rapid revenue growth but also net losses.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement